Rich Shuler, president and chief executive officer of Ivy Animal Health, announced the purchase of Compudose and Encore growth promoting implants from Elanco Animal Health.
According to the terms of the agreement, Ivy receives the rights to the Compudose trademark, the NADA approvals for both products, the patented controlled-release technology, as well as the patented manufacturing technology and equipment. Ivy becomes the exclusive, worldwide manufacturer of Compudose and Encore. In addition, Ivy has entered into a long-term distribution agreement with Elanco to market and distribute Compudose and Encore, in all markets, outside the United States.
Purchasing Elanco's implant product line as well as the controlled release patents and technology is an important part of Ivy Animal Health's targeted growth and acquisition strategy. Shuler said, "Ivy has been marketing Compudose and Encore implant products through its VetLife division for more than five years. Owning the controlled release patents and manufacturing equipment fits perfectly with our core business and will enable Ivy to extend the technology to other animal health compounds and products."
Dave Gordon, executive director, Elanco Animal Health, says the agreement was an excellent fit for both companies' long-term strategies. Gordon said, "In the past five years, through VetLife, Ivy has become the industry leader in growth promoting implants and new implant technologies. They are focused on the product line and will be able to maximize this unique, controlled release technology."
Ivy is manufacturing Compudose and Encore implants at its recently expanded manufacturing facility in Overland Park, KS.